Startups
Developing the next generation bacterial cancer therapy
The vision of T3 Pharmaceuticals is to improve the lives of cancer patients with highly innovative treatments. Despite significant advances of classical therapies, there remains a high need for novel and innovative medicines to treat cancer. T3 Pharmaceuticals is dedicated to fill this gap by developing highly specific and efficient treatments using live bacteria.
T3 Pharmaceuticals was founded in May 2015 by Simon Ittig, Christoph Kasper, Marlise Amstutz and Helmut Kessmann as a spin-off of the University of Basel. The team has developed an efficient protein delivery technology that is based on the use of live bacteria. While the technology has diverse applications in research, T3 Pharma has further developed the system to serve as a novel therapeutic to treat solid tumors.
The vision of T3 Pharmaceuticals is to improve the lives of cancer patients with highly innovative treatments. Despite significant advances of classical therapies, there remains a high need for novel and innovative medicines to treat cancer. T3 Pharmaceuticals is dedicated to fill this gap by developing highly specific and efficient treatments using live bacteria.
T3 Pharmaceuticals was founded in May 2015 by Simon Ittig, Christoph Kasper, Marlise Amstutz and Helmut Kessmann as a spin-off of the University of Basel. The team has developed an efficient protein delivery technology that is based on the use of live bacteria. While the technology has diverse applications in research, T3 Pharma has further developed the system to serve as a novel therapeutic to treat solid tumors.
Overview
Location
Switzerland, Basel-City, Basel
Employees
11-50
Total raised
$27.16M
Founded date
2015
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 23
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Apr 28, 2023 | Swiss Accelerator: Innosuisse supports 53 companies with CHF112 million | |
| Sep 8, 2021 | EY stellt Gründerinnen und Gründer ins Rampenlicht | |
| Sep 2, 2021 | Fünf Unternehmerinnen und Unternehmer am SEF 2021 ausgezeichnet | |
| Jun 10, 2021 | Die Finalisten des Swiss Economic Award stehen fest | |
| Jul 22, 2020 | T3 Pharma Raises CHF25M in Third Funding | T3 Pharmaceuticals AG, a Basel, Switzerland-based biotech advancing immuno-oncology with its bacteria-based protein delivery platform, closed its third financing round, raising over 25M CHF. The round was co-led by existing investors the Bo... |
| Jul 22, 2020 | T3 Pharma raises CHF 25M to advance bacterial cancer therapy | Founded in 2015 as a spin-off from the Biozentrum of the University of Basel, T3 Pharma built a proprietary protein delivery platform by repurposing the bacterial type III secretion (T3S) system. ts lead product, T3P-Y058-739 T3P-Y058-739 i... |
| Jul 22, 2020 | T3 Pharma raises CHF 25M to advance bacterial cancer therapy | |
| Sep 26, 2019 | Financing Round Paves the Way for T3 Pharma to Enter the Clinic | |
| May 28, 2019 | CHF 750‘000 awarded at the 30th De Vigier 2019 Award ceremony |
Show more
Reviews 0
FAQ about T3 Pharmaceuticals AG
When was T3 Pharmaceuticals AG founded?
T3 Pharmaceuticals AG was founded in 2015.
How much funding has T3 Pharmaceuticals AG raised?
T3 Pharmaceuticals AG has raised $27.16M in total across 1 funding round.
What has the press written about T3 Pharmaceuticals AG?
Parsers VC has collected 23 articles mentioning T3 Pharmaceuticals AG, among them “Swiss Accelerator: Innosuisse supports 53 companies with CHF112 million” (Apr 28, 2023) and “EY stellt Gründerinnen und Gründer ins Rampenlicht” (Sep 8, 2021).
Is T3 Pharmaceuticals AG still active?
Yes, T3 Pharmaceuticals AG is active; its latest activity on Parsers VC dates from Nov 22, 2023.